Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.26 USD | +6.10% | +11.39% | +23.96% |
05-15 | Wells Fargo Starts WAVE Life Sciences With Overweight Rating, $11 Price Target | MT |
05-09 | Transcript : Wave Life Sciences Ltd., Q1 2024 Earnings Call, May 09, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+23.96% | 723M | |
+9.42% | 114B | |
+11.84% | 104B | |
-14.15% | 22.41B | |
-1.05% | 22.28B | |
-5.29% | 19.07B | |
-38.29% | 18B | |
-4.16% | 17.89B | |
+7.99% | 14.28B | |
+36.24% | 12.55B |
- Stock Market
- Equities
- WVE Stock
- News Wave Life Sciences Ltd.
- WAVE Life Sciences' Study of WVE-004 to Treat ALS, Dementia Shows No Evidence of Benefits; Shares Tumble 27% Pre-Bell